Friday, 9 October 2026
Independent coverage of global markets, trade and finance
Trading
National Trade News capital-markets note (2026-10-09): Alumis Reports Positive Phase 3 Data With Envudeucitinib (RTTNews) - Alumis (ALMS) announced envudeucitinib data from the ONWARD Phase 3 clinical… Primary source: original at Nasdaq Market Structure (nasdaq.com).
Alumis Reports Positive Phase 3 Data With Envudeucitinib
(RTTNews) - Alumis (ALMS) announced envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3. The company said the results reinforced the potential of envudeucitinib to become a leading oral therapy for patients with moder